Menu

Pharmaceuticals

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival

, , ,

Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer INDIANAPOLIS, March 20, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent […]

Late-breaking Data Shows the Cardiomems HF System Is Effective in Reducing Heart Failure Hospitalizations and Cost of Care

, , , ,

Presented at ACC and published in Journal of American College of Cardiology, the CardioMEMS™ HF System offers sustained benefits for patients suffering from symptomatic heart failure Heart failure hospitalizations cut nearly in half and an average reduction of $10,500 in comprehensive health care costs six months following implant WASHINGTON, March 19, 2017 /PRNewswire/ — New […]

Late-breaking Data on Abbott’s Mitraclip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease

, , , ,

92.8% procedural success observed in reducing leaky heart valve 80.0% of those treated free from repeat heart failure re-hospitalization 85.9% of patients were discharged to home after two-day average hospital stay WASHINGTON, March 18, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip […]

Data on Absorb Bioresorbable Stent Show Comparable Outcomes to Leading Drug-eluting Stent Between One and Two Years

, , , ,

Results emphasize importance of proper vessel sizing and following current instructions for use for optimal clinical outcomes WASHINGTON, March 18, 2017 — Abbott today announced that data from the ABSORB III U.S. pivotal trial showed that Absorb, Abbott’s first-of-its-kind dissolving stent, had comparable efficacy and safety results to XIENCE, Abbott’s leading metallic drug-eluting stent, between […]

First dedicated outcome trials of empagliflozin in chronic heart failure initiated

, , ,

EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes Heart failure affects 26 million people worldwide, and 5.7 million people in the U.S., and is associated with high morbidity and mortality EMPEROR HF will include approximately 7,000 […]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

, , , , ,

Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab Vedotin KENILWORTH, N.J. March 14, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the […]

Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer

, , , , ,

KENILWORTH, N.J. March 14, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for previously treated patients with advanced microsatellite instability-high (MSI-H) […]

New Study Results May Lead to a New Standard of Care for in Vitro Fertilization Treatment

, , , ,

Oral Dydrogesterone has the potential to become new treatment of choice for an estimated 1.5 million women worldwide who undergo IVF treatment each year (1, 2) ABBOTT PARK, Ill., March 8, 2017 /PRNewswire/ — New study results published in Human Reproduction could pave the way for an additional treatment option for the estimated 1.5 million […]

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

, , , , ,

Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA ® (sitagliptin) or Metformin KENILWORTH, N.J. & NEW YORK – March 6, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review […]

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly’s Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

, , ,

Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /CNW/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients […]

«‹ 5 6 7 8›»